Prospective evaluation of18F- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels (2019)
"
Results: PSA values ranged from 0.23 to 698 ng/mL (mean ± SD: 21.6 ± 99.6) in this cohort. The observed 18F-DCFPyL PET/CT-positivity rate was 82% (41 positive scans and 9 negative scans). Uptake in the prostate bed was noted in 15 scans, in lymph nodes in 27 scans, in the skeleton in 19 scans, and in other visceral sites such as the lung, the adrenal gland and liver in 8 scans. Positivity rates were 47% (7/15) for PSA<1ng/mL, 100% (4/4) for PSA 1-2 ng/mL, 90% (9/10) for PSA 2-5 ng/mL, and 100% (21/21) for PSA >5 ng/mL.
Putative sites of disease were detected with PSA as low as 0.4 ng/mL. PSA velocity values were 16.59±42.50 ng/ml/year (range: 0.18-140.3) in patients with positive 18F-DCFPyL PET scans and 0.72±1.17 ng/ml/year (range: 0.05-3.76) in patients with negative 18F-DCFPyL PET scans.
Conclusion: 18F-DCFPyLuptake in multiple areas compatible with BCR PC suggests that 18F- DCFPyL PET imaging use in clinical practice localizes disease in a large proportion of patients, including at very low PSA values."
18F-Fluciclovine for the restaging of patients with biochemical recurrence of prostate cancer and the correlation with PSA values: Results from a single centre (2018)
"
Results Between February and October 2017, 48 patients were scanned. One (2.1%) patient had a baseline PSA between 0.1 and 0.2 ng/mL, 9 (19%) patients >0.2-0.5, 4 (8.3%) patients >0.5-1.0, 6 (13%) patients >1.0-2.0, 14 (29%) patients >2.0-5.0, and 14 (29%) patients had a PSA level >5.0 ng/mL. 18F-Fluciclovine detected lesions in 37 (77%) patients; lesions were detected in the prostate/prostate bed and in pelvic lymph nodes in 19 (40%) and 16 (33%) patients, respectively. Metastatic involvement outside the pelvis was detected in 6 (13%) patient scans, while 10 (21%) scans showed lesions in skeletal sites. Generally, the detection rate increased with increasing baseline PSA, with detection rates of 0%, 78%, 75%, 50%, 86% and 93% among patients with baseline PSA levels in the range 0.1-0.2, >0.2-0.5, >0.5-1.0, >1.0-2.0, >2.0-5.0, and >5.0 ng/mL, respectively.
Conclusions In line with previous studies, 18F-fluciclovine was able to sensitively detect BCR of prostate cancer, even at PSA levels ≤0.5 ng/mL. 18F-Fluciclovine PET/CT shows utility for the detection of disease in the prostate/bed, as well as in extraprostatic tissue and bone."
[Emphasis mine]
Post Edited (DjinTonic) : 3/6/2020 1:50:55 PM (GMT-7)